GlassScriptPhysician profile
Kaieli M Jeter
NPI 1528439668
$4,084.28
in general payments reported to CMS, 2019-2025
22 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $718 · 2023: $876 · 2024: $893 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $537.76 | 2023-2025 | |
| Vifor Pharma, INC. | $448.52 | 2021-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $433.47 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $420.45 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $365.97 | 2021-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $359.85 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $284.99 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $196.62 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $185.87 | 2022-2025 | Ultomiris, Soliris |
| Amgen INC. | $167.88 | 2021-2024 | Parsabiv, Tavneos, Aranesp |
| Akebia Therapeutics INC | $95.28 | 2023-2024 | Auryxia, Vafseo |
| Ardelyx, INC. | $87.22 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $84.41 | 2022-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.57 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $71.67 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $59.70 | 2021-2025 | Symplicity G3 |
| Ultragenyx Pharmaceutical INC. | $45.87 | 2021 | |
| Lilly USA, LLC | $42.27 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $35.65 | 2022-2023 | Velphoro |
| Daiichi Sankyo INC. | $34.89 | 2022 | |
| Glaxosmithkline, LLC. | $33.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaieli Jeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.